The specific application of HDAC6 inhibition in cancer remains uncertain, and there is considerable debate regarding the selectivity of HDAC6-targeting compounds, such as ricolinostat, which exhibit antiproliferative effects at concentrations exceeding the drug’s selective range. This evidence concerns the gene HDAC6 and cancer.